Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989;37(5):477-81.
doi: 10.1007/BF00558127.

CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia

Affiliations
Clinical Trial

CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia

C N Corder et al. Eur J Clin Pharmacol. 1989.

Abstract

CI-924 (CI), 5,5'-[[1,1'-biphenyl]-2,5-diylbis(oxy)]bis[2,2- dimethylpentanoic acid] is chemically similar to gemfibrozil. Patients with Type II (n = 13) and Type IV (n = 22) hyperlipoproteinaemia (HLP) were maintained 12 weeks on a baseline diet containing 55% sugar, 15% protein 30% fat and less than 300 mg cholesterol daily to stabilize weight and lipids. They were then entered in a parallel group double-blinded protocol and received 0, 300, 600, or 1200 mg CI p.o. daily for 12 weeks. CI consistently elevated anti-atherogenic HDL and lowered VLDL at 600 mg/day in both Type II and Type IV HPL at 8 weeks. In Type II patients, CI lowered cholesterol, decreased LDL/HDL and increased ApoA-I. In Type IV patients, CI also lowered TC while elevating LDL and ApoA-II. CI had no effect on Apo-B, LDL-ApoB, or Apo-E.

PubMed Disclaimer

References

    1. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
    1. Clin Chem. 1973 May;19(5):476-82 - PubMed
    1. J Med Chem. 1983 Jul;26(7):1020-7 - PubMed
    1. Artery. 1983;12(1):1-23 - PubMed
    1. Clin Chem. 1976 Jan;22(1):98-101 - PubMed

Publication types

MeSH terms

LinkOut - more resources